S&P Futures
4,005.25 -14.50 (-0.36%) Dow Futures
32,074.00 -46.00 (-0.14%) Nasdaq Futures
12,308.00 -74.75 (-0.60%) Russell 2000 Futures
1,783.00 -6.50 (-0.36%) Crude Oil
110.29 -0.20 (-0.18%) Gold
1,800.70 -7.50 (-0.41%)
Alligator Bioscience AB (publ) (ATORX.ST)
Chart Events
Performance Outlook
| Previous Close | 1.7500 |
| Open | 1.8860 |
| Bid | 1.7200 x 0 |
| Ask | 1.7340 x 0 |
| Day's Range | 1.7020 - 1.8860 |
| 52 Week Range | 1.5600 - 7.2000 |
| Volume | |
| Avg. Volume | 117,244 |
| Market Cap | 379.406M |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7100 |
| Earnings Date | Apr 25, 2022 - Apr 29, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.75 |
- PR Newswire
Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of the patient enrollment for the 600 mg dose cohort from Alligator's Phase I, first-in-human clinical trial with the 4-1BB (CD137) targeting drug candidate, ATOR-1017, which is being developed as a tumor-directed therapy for
- PR Newswire
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line metastatic pancreatic cancer with the company's lead asset, mitazalimab. Safety evaluation of the second dose-escalation cohort (900 µg/kg of mitazalimab in combination with mFOLFIRINOX) has concluded, which marks the successful completion of the Phase Ib part of the study. The Data Review Committee has declared the 900 µg/kg mitazalimab dose to be safe and
- PR Newswire
Alligator Bioscience AB: Year End report January-December 2021
OPTIMIZE-1 Phase II - On Track and Moving Forward
